Postmenopausal ER+ breast cancer: toremifene tops letrozole for lipid, bone metabolism

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • The adjuvant hormone therapy toremifene (TOR) has more favorable effects on lipid and bone metabolism than letrozole (LET) in postmenopausal, estrogen receptor (ER) -positive breast cancer.

Why this matters

  • TOR would be the better choice for patients who are elderly, have...